Caprelsa
(vandetanib)ApprovedSmall molecule
Vandetanib is used to treat certain types of thyroid cancer that have spread or cannot be removed by surgery. It works by slowing or stopping the growth of cancer cells.[2] Caprelsa is currently approved and in use across 34 indications[4].[1]
Caprelsa is one of 728 small molecule programs targeting Glioma. It is currently in Approved.
34
Indications
63
Total Trials
3
Active Trials
727
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Caprelsa
GGenzyme, a Sanofi Company
Approved
Tecentriq
RochePreclinical
Tykerb
GSKPreclinical
Prolia
AmgenPreclinical
DATROWAY
Daiichi SankyoPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Cancer10 trials
Show 7 more trials
Breast Cancer6 trials
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
Completed·—·Phase 1·NCT00496665·25 enrolled
Patients With Advanced Solid Tumors2 trials
Chemotherapy2 trials
37 more indications
Prostate Cancer2 trials
Glioma2 trials
Colorectal Cancer2 trials
Tics2 trials
Primary Peritoneal Cancer1 trial
Urinary Tract Cancer1 trial
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Completed·—·Phase 2·NCT01191892·82 enrolled
Randomized1 trial
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Completed·—·Phase 2·NCT00880334·149 enrolled
Malignant Mesothelioma1 trial
Fallopian Tube Cancer1 trial
Intestinal Cancer1 trial
Metformin1 trial
Thyroid Carcinoma1 trial
Metastatic NSCLC1 trial
Gastroesophageal Junction Cancer1 trial
Papillary Renal Cell Carcinoma1 trial
Paraganglioma1 trial
Efficacy1 trial
Midazolam1 trial
Treatment1 trial
Liposomal Doxorubicin1 trial
Lung Carcinoma1 trial
Radiation Therapy1 trial
Metastatic Cancer1 trial
Gastrointestinal Stromal Tumor1 trial
Gastroesophageal Junction1 trial
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Terminated·—·Phase 1·NCT00732745·9 enrolled
Non-Small Cell Lung Cancer1 trial
Relapsed or Refractory1 trial
Metastatic Colorectal Cancer1 trial
Hepatocellular Carcinoma1 trial
Malignant Glioma1 trial
Lymphoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 6, 2011
CAPRELSA
NDA NDA022405
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Caprelsa drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for vandetanib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Ephrin Receptor Inhibitor; Tyrosine-Protein Kinase BRK Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Epidermal Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase SRC Inhibitor; Tyrosine-Protein Kinase TIE-2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGenzyme, a Sanofi Company
Patent Landscape[6]
Patent Cliff
Aug 8, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8067427Aug 8, 2028